Precision Biosensor, Inc.
KKRX:3358101,464.00
KRW
-10.00
(-0.68%)
ISIN
KR7335810008
Return %
Stock
S&P 500
1Y
-50.87
14.39
3Y
-73.14
81.42
5Y
-88.00
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Han-Sin Kim
- Full Time Employees
- 97
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Daejeon South Korea
- IPO Date
- Dec 22, 2020
- Website
- precision-bio.com
- Similar Companies
- Business
- Precision Biosensor, Inc. is a South Korea-based in-vitro diagnostics (IVD) company that specializes in the development, manufacture, and commercialization of point-of-care testing (POCT) platforms and diagnostic assay kits. The company operates primarily through two core diagnostic business segments: Immunodiagnostics and Clinical Chemistry. Its product portfolio comprises diagnostic instruments and consumable test cartridges, including the Exdia TRF and Exdia TRF Plus immunoassay analyzers utilizing Time-Resolved Fluorescence (TRF) optical technology for high-sensitivity quantitative testing; immunodiagnostic cartridges for cardiac markers (including Troponin I, CK-MB, Myoglobin, D-Dimer, and NT-proBNP); inflammatory and sepsis markers (including C-reactive protein [CRP] and Procalcitonin [PCT]); infectious disease test kits (including COVID-19 Ag, Influenza A+B, Norovirus, and RSV); the Exdia PT10 and Exdia PT10S automated clinical chemistry analyzers utilizing microfluidic lab-on-a-chip technology for multi-parameter biochemical testing; comprehensive clinical chemistry test cartridges for liver function, renal function, lipid profiles, diabetes, and electrolyte panels; the Exdia PT10V clinical chemistry analyzer and dedicated test panels tailored for veterinary medicine; and rapid diagnostic test kits marketed under the Nano-Check and PBCheck brand lines. Precision Biosensor distributes its products to hospitals, clinics, emergency rooms, diagnostic laboratories, and veterinary facilities across South Korea, Europe, North America, the Middle East, and the Asia-Pacific region. In recent strategic developments, Kwangdong Pharmaceutical Co., Ltd. entered into an agreement to acquire a controlling 29.7% equity stake in Precision Biosensor for approximately 17 billion won from i-SENS, Inc. and existing shareholders, creating a strategic partnership to expand into personalized healthcare and chronic disease management. Furthermore, the company continues to scale its global commercial presence by expanding distribution networks across major European markets and driving international commercialization through its wholly owned United States subsidiary, Nano-Ditech Corp. Established in 2015 through the merger of Terawave, Inc. and Nano-Ditech Corp., Precision Biosensor, Inc. is headquartered in Daejeon, South Korea, and is listed on the KOSDAQ under the ticker 335810.